Subhallucinogenic Concentrations of Substituted Phenethylamines as a Novel Therapeutic Approach for Inflammatory and Neurological Disorders.
ACS medicinal chemistry letters – July 13, 2023
Source: PubMed
Summary
A novel therapeutic strategy suggests that specific compounds, at doses too low to cause hallucinations, could effectively treat inflammatory and neurological conditions. This approach involves administering precise, sub-hallucinogenic concentrations of substituted phenethylamines, such as 2C-H or 2C-B. Dosing is tailored to disease severity, with 25-100mg proposed to alleviate symptoms. This method offers a promising new avenue for managing chronic disorders.
Abstract
This Patent Highlight presents a method to treat inflammatory or neurological disorders in subjects needing treatment. The method involves administering a therapeutically effective amount of a composition containing a subhallucinogenic concentration of substituted phenethylamine. The substituted phenethylamine may belong to the 2C-X family, including 2C-H, 2C-I, 2C-B, or 2C-E. The specific concentration depends on the chronic inflammation's severity, with 25 mg for mild, 50 mg for moderate, and 100 mg for severe cases.